SCHEMBL15420798

SCHEMBL15420798

Cc1cnn(-c2ccc(OC[C@H]3OCCC[C@@H]3NS(C)(=O)=O)c(F)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.40
KAT6A Q92794 2/20 0.35
KAT5 Q92993 1/20 0.34
INSR P06213 3/20 0.34
ALK Q9UM73 3/20 0.34
RIPK2 O43353 1/20 0.34
PRKCQ Q04759 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HCRTR2 O43614 5/20 0.33
SYK P43405 1/20 0.32
BRD4 O60885 1/20 0.32
PIK3CA P42336 1/20 0.32
ROS1 P08922 1/20 0.32
RXRA P19793 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21795661 1.00 SCN9A (0.40) SCN9AKAT6AKAT5INSRALK
SCHEMBL21795637 0.92 SCN9A (0.36) SCN9AKAT6AKAT5RIPK2PRKCQ
SCHEMBL15420670 0.92 SCN9A (0.36) SCN9AKAT6AKAT5RIPK2PRKCQ
SCHEMBL15420504 0.92 SCN9A (0.35) SCN9AKAT6AKAT5ALKRIPK2
SCHEMBL21795675 0.91 SCN9A (0.38) SCN9AINSRALKRIPK2PRKCQ
SCHEMBL15420693 0.91 SCN9A (0.38) SCN9AINSRALKRIPK2PRKCQ
SCHEMBL15419966 0.86 RAB9A (0.39) KAT5INSRALKRIPK2ROS1
SCHEMBL15420735 0.84 KAT5 (0.38) SCN9AKAT6AKAT5INSRALK
SCHEMBL15420287 0.83 SCN9A (0.35) SCN9AKAT5INSRALKRIPK2
SCHEMBL15420702 0.83 KAT5 (0.38) SCN9AKAT6AKAT5INSRALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 SCN9A 648/4885KAT6A 1800/4885KAT5 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.